Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1
Publication Type:
Journal Article
Authors:
D L Wyles;
P J Ruane;
M S Sulkowski;
D. Dieterich;
Luetkemeyer, A.;
Morgan, T.R.;
Sherman, K.E.;
Dretler, R.;
Fishbein, D.;
Gathe, J.C., Jr.;
Henn, S.;
Hinestrosa, F.;
Huynh, C.;
McDonald, C.;
Mills, A.;
Overton, E.T.;
Ramgopal, M.;
Rashbaum, B.;
Ray, G.;
Scarsella, A.;
Yozviak, J.;
McPhee, F.;
Liu, Z.;
Hughes, E.;
Yin, P.D.;
Noviello, S.;
Ackerman, P.;
ALLY-2 InvestigatorsSource:
N Engl J Med, Volume 373, Issue 8, p.714-725 (2015)
Keywords:
Alabama,
Antiretroviral,
Antiretroviral Therapy,
California,
Colorado,
Disease,
Fatigue,
Florida,
Genotype,
genotype 1,
HCV,
Headache,
Health,
hepatitis,
Hepatitis C,
hepatitis C virus,
Hiv-1,
Human,
immunology,
Infection,
Liver,
Los Angeles,
medication,
Medicine,
methods,
Nausea,
New York,
NS5A inhibitor,
NS5B inhibitor,
Patients,
Research,
Safety,
San Francisco,
sofosbuvir,
sustained virologic response,
Texas,
therapy,
treatment,
Universities,
Veterans,
Washington
